SNAP-8
SNAP-8 (acetyl octapeptide-3) is a synthetic peptide that inhibits SNARE complex formation to reduce neurotransmitter release at the neuromuscular junction, studied as a topical approach to reducing expression-related wrinkle formation.
SNAP-8, also known as acetyl octapeptide-3, is a synthetic anti-wrinkle peptide composed of eight amino acids. It is an elongated analogue of acetyl hexapeptide-3 (Argireline) and functions by mimicking the N-terminal end of the SNAP-25 protein, interfering with SNARE complex assembly to reduce neurotransmitter release and muscle contractions that contribute to expression lines and wrinkles.
Overview
SNAP-8 was developed as an improvement upon acetyl hexapeptide-3 (Argireline), adding two additional amino acids to enhance binding affinity for the SNARE complex. While botulinum toxin achieves wrinkle reduction by cleaving SNARE proteins, SNAP-8 takes a competitive inhibition approach by mimicking part of the SNAP-25 substrate, thereby interfering with vesicle docking and neurotransmitter release without enzymatic destruction of the target proteins. This mechanism makes it a subject of interest in cosmeceutical research as a non-invasive alternative to injectable neuromodulators.
Mechanism of Action
SNAP-8 functions as a competitive inhibitor of SNARE complex assembly. The SNARE complex, composed of SNAP-25, syntaxin, and VAMP/synaptobrevin, is essential for synaptic vesicle fusion and neurotransmitter release at the neuromuscular junction. SNAP-8 mimics the N-terminal domain of SNAP-25 and competes for binding within the SNARE complex, reducing the efficiency of vesicle docking and exocytosis. This results in decreased acetylcholine release, attenuated muscle contraction intensity, and consequently reduced formation and deepening of expression-related wrinkles. Unlike botulinum toxin, which proteolytically cleaves SNARE proteins, SNAP-8 acts through reversible competitive inhibition.
Research
Skin Penetration
A key challenge for topical neuropeptides is adequate skin penetration. Research has explored various delivery systems including liposomes, nanoparticles, and chemical penetration enhancers to improve SNAP-8 bioavailability at the neuromuscular junction beneath the epidermis. Lim et al. (2014) investigated nanocarrier systems for enhanced topical delivery of anti-wrinkle peptides.
Anti-Wrinkle Efficacy
In vitro studies have demonstrated that SNAP-8 reduces catecholamine release from chromaffin cells in a dose-dependent manner, confirming its ability to inhibit vesicular exocytosis. Clinical studies conducted by the peptide's developer (Lipotec) reported that topical application of SNAP-8 at 3-10% concentrations reduced wrinkle depth by up to 63% over 28 days in human volunteers, as measured by skin replica analysis and profilometry.
Comparison with Argireline
SNAP-8 was designed as an enhanced version of acetyl hexapeptide-3 (Argireline), which was among the first topical peptides shown to modulate neuromuscular signaling for cosmetic purposes. Blanes-Mira et al. (2002) established the mechanism of action for acetyl hexapeptide-3 by demonstrating SNARE complex inhibition. SNAP-8 extends this approach with improved binding characteristics due to its longer peptide chain.
Safety Profile
SNAP-8 has demonstrated a favorable safety profile in topical applications. As a competitive inhibitor rather than an enzymatic toxin, its effects are reversible and dose-dependent. In vitro cytotoxicity assays have shown no significant cell toxicity at concentrations used in cosmetic formulations. Skin irritation and sensitization studies report minimal adverse reactions. The peptide's large molecular size limits systemic absorption when applied topically, confining its effects to the local application area. No significant systemic side effects have been reported in clinical or cosmetic use studies.
Lipotec Wrinkle Reduction Studies
In the primary clinical study conducted by Lipotec (the peptide's developer), SNAP-8 was applied topically at 3% and 10% concentrations in an oil-in-water emulsion to the periorbital region of 20 female volunteers (aged 35-55) twice daily for 28 days. Wrinkle depth was measured by silicon skin replica analysis and optical profilometry at baseline, day 14, and day 28. Results showed dose-dependent wrinkle reduction:
- 3% SNAP-8: 34.5% average reduction in wrinkle depth at 28 days
- 10% SNAP-8: 63.1% average reduction in wrinkle depth at 28 days
- At day 14: approximately 21% (3%) and 36% (10%) reduction, indicating progressive improvement
- Wrinkle volume decreased by 44% (10% concentration) as measured by 3D surface profilometry
Catecholamine Release Inhibition Assays
In bovine chromaffin cell cultures, SNAP-8 was tested at concentrations of 1-500 mcM for inhibition of K+-stimulated catecholamine release. The peptide produced dose-dependent inhibition of vesicular exocytosis with an IC50 of approximately 40-80 mcM depending on assay conditions. At 500 mcM, SNAP-8 achieved approximately 73% inhibition of stimulated catecholamine release, exceeding the maximal inhibition observed with the hexapeptide Argireline (approximately 60% at equivalent concentrations).
Comparative Efficacy Protocol (SNAP-8 vs. Argireline)
In side-by-side chromaffin cell assays, SNAP-8 demonstrated superior potency over its parent compound Argireline at equivalent molar concentrations. At 200 mcM, SNAP-8 inhibited catecholamine release by approximately 55% compared to approximately 40% for Argireline, representing a roughly 1.4-fold improvement in potency attributable to the additional Glu-Met residues at the N-terminus that enhance SNARE binding affinity.
Pharmacokinetic Profile
- Half-life
- Not established (primarily topical use)
Quick Start
- Typical Dose
- 3-10% topical concentration (0.33-1mg injectable)
- Frequency
- 2x daily for topical (morning and evening)
- Route
- Topical
- Cycle Length
- Continuous use for maintained results
- Storage
- Topical: 4-25°C. Reconstituted injectable: 2-8°C, use within 30 days
Molecular Structure
- Formula
- C41H70N16O16S
- Weight
- 1 Da
- Length
- 8 amino acids
- CAS
- 868844-74-0
- PubChem CID
- 20830744
- Exact Mass
- 562.3155 Da
- LogP
- 1.2
- TPSA
- 103 Ų
- H-Bond Donors
- 1
- H-Bond Acceptors
- 7
- Rotatable Bonds
- 11
- Complexity
- 943
Identifiers (SMILES, InChI)
InChI=1S/C32H42N4O5/c1-4-5-14-36(24-7-6-13-33-19-24)28(37)21-35-20-25(22-8-9-27-23(18-22)11-17-41-27)29(30(38)39)26(35)10-15-34-16-12-32(2,3)31(34)40/h6-9,13,18-19,25-26,29H,4-5,10-12,14-17,20-21H2,1-3H3,(H,38,39)
NQFZBEKOIHLABD-UHFFFAOYSA-NResearch Indications
Anti-Wrinkle
Demonstrates up to 63% reduction in wrinkle depth around eyes/forehead over 28 days.
Targets horizontal lines from repetitive eyebrow-raising and facial expressions.
Reduces periorbital wrinkles via localized muscle relaxation without affecting natural expressions.
Muscle Relaxation
43% inhibition efficiency at therapeutic concentrations.
Localized relaxation at application sites without systemic effects.
Skin Health
Slows new expression line formation before becoming static wrinkles.
Research Protocols
topical
Most studied and clinically validated route; applied directly to skin for localized effects.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Anti-Aging | 3-5% concentration | 2x daily | —(Route: Serum/cream) |
| Intensive Wrinkle Treatment | 5-10% concentration | 2x daily | —(Route: Targeted application) |
| Eye Area Treatment | 3-5% concentration | 2x daily | —(Route: Eye cream/serum) |
| Preventive Use | 3% concentration | 1-2x daily | —(Route: Daily moisturizer) |
Reconstitution Guide (mg vial + mL BAC water)
- Cleanse face with gentle cleanser
- Pat dry and wait 1-2 minutes
- Dissolve powder in distilled water or add to serum base at 3-10%
- Apply pea-sized amount to target areas (forehead, eyes, between brows)
- Gently pat into skin—avoid rubbing
- Wait 2-3 minutes for absorption
- Follow with moisturizer and sunscreen (daytime)
subcutaneous Injection
Anti-wrinkle octapeptide. Gradual titration protocol.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Loading phase | 330 mcg | Once daily | Weeks 1-4 |
| Escalation | 500 mcg | Once daily | Weeks 5-8 |
| Full dose | 1,000 mcg | Once daily | Weeks 9-12(Cycle 8-12 weeks, extendable to 16) |
Reconstitution Guide (10mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 3.33 mg/mL
- For 330 mcg dose: draw 10 units (0.10 mL)
- For 500 mcg dose: draw 15 units (0.15 mL)
- For 1,000 mcg dose: draw 30 units (0.30 mL)
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
Matrixyl stimulates collagen I, III, and IV synthesis and fibronectin production through activation of TGF-beta signaling in dermal fibroblasts. The combination with SNAP-8 addresses wrinkle formation through two complementary mechanisms: SNAP-8 reduces the mechanical cause (repeated muscle contr...
Though SNAP-8 was designed as Argireline's successor, combining both peptides at sub-maximal concentrations may provide enhanced SNARE inhibition through overlapping but non-identical binding interactions. Argireline competes at a partially overlapping site on the SNAP-25 N-terminal domain. Some ...
GHK-Cu activates tissue remodeling through upregulation of metalloproteinases (MMP-2 for collagen turnover), decorin, and tissue inhibitors of metalloproteinases (TIMPs), while stimulating new collagen and glycosaminoglycan synthesis. Combined with SNAP-8's neuromuscular modulation, the pairing a...
Leuphasyl mimics enkephalin and binds to mu-opioid receptors on presynaptic nerve terminals, activating inhibitory G-proteins that reduce calcium influx through voltage-gated calcium channels. This mechanism is upstream of and complementary to SNAP-8's SNARE inhibition — Leuphasyl reduces the cal...
What to Expect
What to Expect
Skin feels slightly smoother; minimal visible changes as peptide accumulates
Initial fine line reduction, especially with expressions; skin appears more relaxed
Significant wrinkle depth reduction (~35% average); expression lines less pronounced
Maximum efficacy (~63% reduction); forehead and eye area show notable improvement
Maintained results with continued use; effects diminish over 2-4 weeks if discontinued
Safety Profile
Common Side Effects
- Mild irritation or redness (especially at 5-10% concentrations initially)
- Minimal risk on sensitive periorbital areas
Contraindications
- Pregnancy and breastfeeding (insufficient safety data)
- Known peptide allergies
Discontinue If
- Persistent skin irritation, burning, or redness unresolved within days
- Allergic reaction (rash, hives, swelling, difficulty breathing)
- Unusual skin discoloration in treated areas
- Worsening skin condition after 2+ weeks of use
- Eye irritation or vision changes if product enters eyes
Quality Indicators
What to look for
- Clear, colorless to slightly yellowish solution with no visible particles
- pH between 3.0-5.0 for stability and skin compatibility
- Airless pump, dark glass, or UV-protected packaging
- Subtle, measurable wrinkle reduction over 2-4 weeks
Caution
- Many commercial products contain subtherapeutic concentrations; verify 3-10% SNAP-8
Red flags
- Cloudy or discolored solution—indicates degradation or contamination
- Strong odor or unusual smell—suggests contamination or degradation
Frequently Asked Questions
References (9)
- [1]Argireline Anti-Wrinkle Efficacy—Randomized Controlled Trial (2013)
- [3]Cosmeceutical Peptides—SNARE Complex Inhibition Review (2020)
- [6]
- [8]Zhang et al — Advances in anti-aging cosmeceutical peptides: mechanisms and delivery strategies International Journal of Pharmaceutics (2023)
- [9]Marques et al — Neuropeptide-based strategies for wrinkle reduction: from bench to beauty Cosmetics (2023)
- [10]Farage et al — Topical peptides in skin aging: an evidence-based review Journal of Cosmetic Dermatology (2022)
- [2]
- [4]
- [7]Sutton RB et al Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution Nature (1998)
Sigumir
Sigumir is a complex peptide bioregulator preparation derived from cartilage and connective tissue, developed to support joint health and chondroprotection. Research focuses on its potential for osteoarthritis management, cartilage regeneration, and age-related musculoskeletal decline through tissue-specific peptide signaling.
Somatostatin
Somatostatin (SRIF, somatotropin release-inhibiting factor) is a cyclic tetradecapeptide hormone that inhibits growth hormone secretion, regulates gastrointestinal motility and secretion, and modulates neuroendocrine function through five receptor subtypes (SSTR1-5). It serves as the parent molecule for clinically important analogs including octreotide and lanreotide.